Parallel Trade in Polish Pharma: The Good and the Bad
Poland’s entrance into the EU has been a catalyst for growth that has allowed the country to flourish, shown by the nation’s ranking as the eighth largest economy in Europe according…
Address: Al. Armii Ludowej 26
00-609 Warsaw
Tel: +48 22 579 66 66
Web: http://www.bms.com/pages/default.aspx
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines are helping millions of patients in their fight against such diseases as cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, psychiatric disorders and rheumatoid arthritis.
Since 2002 the company has delivered nine important new products to patients with serious diseases. Two of these medicines are biologic products. Additional biologic compounds – as well as scores of other investigational medicines – are advancing through the development pipeline. Bristol-Myers Squibb is recognized as having one of the most productive pipelines in the industry.
What sets us apart? As a BioPharma leader, we believe it’s our commitment to patients with serious diseases and our focus on finding innovative medicines to combat those diseases.
And, as we make a difference in the lives of patients, we say, “Together we can prevail.”
http://www.bms.com
Bristol-Myers Squibb in Poland
Squibb Corporation opened its office in Poland in 1968, and Bristol-Myers in 1970. Since 1995 the company is operating in Poland as Bristol-Myers Squibb.
Theapeutic areas:
Oncology
Diabetes
HIV/AIDS
Hepatitis
Central Nervous System
Transplantology
Immunology
http://www.b-ms.pl
Poland’s entrance into the EU has been a catalyst for growth that has allowed the country to flourish, shown by the nation’s ranking as the eighth largest economy in Europe according…
“Cost containment measures are not just a Polish story, but a European reality,” says Marcin Hanczaruk, general manager at Amgen. “The Reimbursement Act is a real revolution, but it has…
The general director of Actavis Poland talks about competing in an intense generics market, and the company’s potential in Poland given the country’s 2012 Reimbursement Act. The year 2012 was…
AstraZeneca’s General Manager in Poland discuses AstraZeneca’s strategic realignment to become a highly specialized biotech company after 20 years of presence in Poland. He stresses the importance of the affiliate’s…
Novascon Pharmaceuticals is the second fastest growing company in the OTC/dietary supplement market in Poland. Its founder shares the reasons behind this success, including his strategy to sell their main…
Omega Pharma is a pharmacist champion and one of the fastest growing OTC companies in Poland. Its General Manager in Poland discusses the shift taking place with Pharmacies now becoming…
Schulke Poland’s General Manager wants the affiliate: “to be recognized as a high quality “one stop shop” for hygiene and disinfection. He also comments: “Poland is quite advanced in terms…
The department of innovation and industry under the Ministry of Economy has been preparing a new project called: “Pharmaceutical Industry Mapping.” Its leader hopes: “that the outcome of this exercise…
Bristol-Myers Squibb’s General Manager in Poland stresses the urgent need to allow more innovative drugs to fight against deadly diseases, especially in the field of immune-oncology which he says will:…
Unipharm Poland’s country manager explains what is needed to become a successful OTC and dietary supplement company in Poland, saying that it is “key to master the marketing mix but…
Budget limitations in the Polish vaccine field are a handicap to improving patients’ lives as Sanofi Pasteur General Manager comments: “the National Health Fund’s budget for reimbursement is around EUR…
“Innovation is about bringing new chemical compounds on the market; but it is also, and sometimes even more, to continue the therapeutic development of the drugs which are already there”…
See our Cookie Privacy Policy Here